OXiGENE, Inc.

Study demonstrates effectiveness of drug in treatment of retinoblastoma

Published in Medicine and Law Weekly, March 11th, 2005

OXiGENE, Inc., (NASDAQ: OXGN, XSSE: OXGN) announced the publication of a preclinical study using local administration of Combretastatin A4P (CA4P) in the treatment of a murine model of retinoblastoma.

The study reported that a subconjunctival delivery of CA4P, a vascular targeting agent (VTA), induces an extensive dose-dependent reduction in blood vessel count leading to significant tumor reduction with no evidence of corneal, lenticular, choroidal or retinal toxicity. CA4P is involved in seven ongoing human oncology trials in the United States and Europe.

"These data provide further evidence of CA4P's ability to attack aberrant blood vessels...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medicine and Law Weekly

Source: Medicine and Law Weekly (2005-03-11)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry